Rapid Serological Assays and SARS-CoV-2 Real-Time Polymerase Chain Reaction Assays for the Detection of SARS-CoV-2: Comparative Study

Real-time polymerase chain reaction (RT-PCR) testing for the identification of viral nucleic acid is the current standard for the diagnosis of SARS-CoV-2 infection, but technical issues limit its utilization for large-scale screening. Serological immunoglobulin M (IgM)/IgG testing has been proposed...

Full description

Saved in:
Bibliographic Details
Published inJournal of medical Internet research Vol. 22; no. 10; p. e19152
Main Authors Paradiso, Angelo Virgilio, De Summa, Simona, Loconsole, Daniela, Procacci, Vito, Sallustio, Anna, Centrone, Francesca, Silvestris, Nicola, Cafagna, Vito, De Palma, Giuseppe, Tufaro, Antonio, Garrisi, Vito Michele, Chironna, Maria
Format Journal Article
LanguageEnglish
Published Canada JMIR Publications 30.10.2020
Subjects
Online AccessGet full text
ISSN1438-8871
1439-4456
1438-8871
DOI10.2196/19152

Cover

Abstract Real-time polymerase chain reaction (RT-PCR) testing for the identification of viral nucleic acid is the current standard for the diagnosis of SARS-CoV-2 infection, but technical issues limit its utilization for large-scale screening. Serological immunoglobulin M (IgM)/IgG testing has been proposed as a useful tool for detecting SARS-CoV-2 exposure. The objective of our study was to compare the results of the rapid serological VivaDiag test for SARS-CoV-2-related IgM/IgG detection with those of the standard RT-PCR laboratory test for identifying SARS-CoV-2 nucleic acid. We simultaneously performed both serological and molecular tests with a consecutive series of 191 symptomatic patients. The results provided by a new rapid serological colorimetric test for analyzing IgM/IgG expression were compared with those of RT-PCR testing for SARS-CoV-2 detection. Of the 191 subjects, 70 (36.6%) tested positive for SARS-CoV-2 based on RT-PCR results, while 34 (17.3%) tested positive based on serological IgM/IgG expression. Additionally, 13 (6.8%) subjects tested positive based on serological test results, but also tested negative based on RT-PCR results. The rapid serological test had a sensitivity of 30% and a specificity of 89% compared to the standard RT-PCR assay. Interestingly, the performance of both assays improved 8 days after symptom appearance. After 10 days had passed since symptom appearance, the predictive value of the rapid serological test was higher than that of the standard molecular assay (proportion of positive results: 40% vs 20%). Multivariate analysis showed that age >58 years (P<.01) and period of >15 days after symptom onset (P<.02) were significant and independent factors associated with serological test positivity. The rapid serological test analyzed in this study seems limited in terms of usefulness when diagnosing SARS-CoV-2 infection. However, it may be useful for providing relevant information on people's immunoreaction to COVID-19 exposure.
AbstractList Real-time polymerase chain reaction (RT-PCR) testing for the identification of viral nucleic acid is the current standard for the diagnosis of SARS-CoV-2 infection, but technical issues limit its utilization for large-scale screening. Serological immunoglobulin M (IgM)/IgG testing has been proposed as a useful tool for detecting SARS-CoV-2 exposure. The objective of our study was to compare the results of the rapid serological VivaDiag test for SARS-CoV-2-related IgM/IgG detection with those of the standard RT-PCR laboratory test for identifying SARS-CoV-2 nucleic acid. We simultaneously performed both serological and molecular tests with a consecutive series of 191 symptomatic patients. The results provided by a new rapid serological colorimetric test for analyzing IgM/IgG expression were compared with those of RT-PCR testing for SARS-CoV-2 detection. Of the 191 subjects, 70 (36.6%) tested positive for SARS-CoV-2 based on RT-PCR results, while 34 (17.3%) tested positive based on serological IgM/IgG expression. Additionally, 13 (6.8%) subjects tested positive based on serological test results, but also tested negative based on RT-PCR results. The rapid serological test had a sensitivity of 30% and a specificity of 89% compared to the standard RT-PCR assay. Interestingly, the performance of both assays improved 8 days after symptom appearance. After 10 days had passed since symptom appearance, the predictive value of the rapid serological test was higher than that of the standard molecular assay (proportion of positive results: 40% vs 20%). Multivariate analysis showed that age >58 years (P<.01) and period of >15 days after symptom onset (P<.02) were significant and independent factors associated with serological test positivity. The rapid serological test analyzed in this study seems limited in terms of usefulness when diagnosing SARS-CoV-2 infection. However, it may be useful for providing relevant information on people's immunoreaction to COVID-19 exposure.
BackgroundReal-time polymerase chain reaction (RT-PCR) testing for the identification of viral nucleic acid is the current standard for the diagnosis of SARS-CoV-2 infection, but technical issues limit its utilization for large-scale screening. Serological immunoglobulin M (IgM)/IgG testing has been proposed as a useful tool for detecting SARS-CoV-2 exposure. ObjectiveThe objective of our study was to compare the results of the rapid serological VivaDiag test for SARS-CoV-2–related IgM/IgG detection with those of the standard RT-PCR laboratory test for identifying SARS-CoV-2 nucleic acid. MethodsWe simultaneously performed both serological and molecular tests with a consecutive series of 191 symptomatic patients. The results provided by a new rapid serological colorimetric test for analyzing IgM/IgG expression were compared with those of RT-PCR testing for SARS-CoV-2 detection. ResultsOf the 191 subjects, 70 (36.6%) tested positive for SARS-CoV-2 based on RT-PCR results, while 34 (17.3%) tested positive based on serological IgM/IgG expression. Additionally, 13 (6.8%) subjects tested positive based on serological test results, but also tested negative based on RT-PCR results. The rapid serological test had a sensitivity of 30% and a specificity of 89% compared to the standard RT-PCR assay. Interestingly, the performance of both assays improved 8 days after symptom appearance. After 10 days had passed since symptom appearance, the predictive value of the rapid serological test was higher than that of the standard molecular assay (proportion of positive results: 40% vs 20%). Multivariate analysis showed that age >58 years (P<.01) and period of >15 days after symptom onset (P<.02) were significant and independent factors associated with serological test positivity. ConclusionsThe rapid serological test analyzed in this study seems limited in terms of usefulness when diagnosing SARS-CoV-2 infection. However, it may be useful for providing relevant information on people’s immunoreaction to COVID-19 exposure.
Real-time polymerase chain reaction (RT-PCR) testing for the identification of viral nucleic acid is the current standard for the diagnosis of SARS-CoV-2 infection, but technical issues limit its utilization for large-scale screening. Serological immunoglobulin M (IgM)/IgG testing has been proposed as a useful tool for detecting SARS-CoV-2 exposure.BACKGROUNDReal-time polymerase chain reaction (RT-PCR) testing for the identification of viral nucleic acid is the current standard for the diagnosis of SARS-CoV-2 infection, but technical issues limit its utilization for large-scale screening. Serological immunoglobulin M (IgM)/IgG testing has been proposed as a useful tool for detecting SARS-CoV-2 exposure.The objective of our study was to compare the results of the rapid serological VivaDiag test for SARS-CoV-2-related IgM/IgG detection with those of the standard RT-PCR laboratory test for identifying SARS-CoV-2 nucleic acid.OBJECTIVEThe objective of our study was to compare the results of the rapid serological VivaDiag test for SARS-CoV-2-related IgM/IgG detection with those of the standard RT-PCR laboratory test for identifying SARS-CoV-2 nucleic acid.We simultaneously performed both serological and molecular tests with a consecutive series of 191 symptomatic patients. The results provided by a new rapid serological colorimetric test for analyzing IgM/IgG expression were compared with those of RT-PCR testing for SARS-CoV-2 detection.METHODSWe simultaneously performed both serological and molecular tests with a consecutive series of 191 symptomatic patients. The results provided by a new rapid serological colorimetric test for analyzing IgM/IgG expression were compared with those of RT-PCR testing for SARS-CoV-2 detection.Of the 191 subjects, 70 (36.6%) tested positive for SARS-CoV-2 based on RT-PCR results, while 34 (17.3%) tested positive based on serological IgM/IgG expression. Additionally, 13 (6.8%) subjects tested positive based on serological test results, but also tested negative based on RT-PCR results. The rapid serological test had a sensitivity of 30% and a specificity of 89% compared to the standard RT-PCR assay. Interestingly, the performance of both assays improved 8 days after symptom appearance. After 10 days had passed since symptom appearance, the predictive value of the rapid serological test was higher than that of the standard molecular assay (proportion of positive results: 40% vs 20%). Multivariate analysis showed that age >58 years (P<.01) and period of >15 days after symptom onset (P<.02) were significant and independent factors associated with serological test positivity.RESULTSOf the 191 subjects, 70 (36.6%) tested positive for SARS-CoV-2 based on RT-PCR results, while 34 (17.3%) tested positive based on serological IgM/IgG expression. Additionally, 13 (6.8%) subjects tested positive based on serological test results, but also tested negative based on RT-PCR results. The rapid serological test had a sensitivity of 30% and a specificity of 89% compared to the standard RT-PCR assay. Interestingly, the performance of both assays improved 8 days after symptom appearance. After 10 days had passed since symptom appearance, the predictive value of the rapid serological test was higher than that of the standard molecular assay (proportion of positive results: 40% vs 20%). Multivariate analysis showed that age >58 years (P<.01) and period of >15 days after symptom onset (P<.02) were significant and independent factors associated with serological test positivity.The rapid serological test analyzed in this study seems limited in terms of usefulness when diagnosing SARS-CoV-2 infection. However, it may be useful for providing relevant information on people's immunoreaction to COVID-19 exposure.CONCLUSIONSThe rapid serological test analyzed in this study seems limited in terms of usefulness when diagnosing SARS-CoV-2 infection. However, it may be useful for providing relevant information on people's immunoreaction to COVID-19 exposure.
Author Sallustio, Anna
De Palma, Giuseppe
Loconsole, Daniela
Silvestris, Nicola
Tufaro, Antonio
Cafagna, Vito
Paradiso, Angelo Virgilio
Chironna, Maria
Centrone, Francesca
Garrisi, Vito Michele
Procacci, Vito
De Summa, Simona
AuthorAffiliation 3 Department of Biomedical Sciences and Human Oncology-Hygiene Section University of Bari Bari Italy
4 Emergency Department Policlinico Hospital Bari Italy
5 Regional Epidemiological Observatory Apulia Region Bari Italy
7 Medical Oncology Unit IRCCS Istituto Tumori Giovanni Paolo II Bari Italy
10 Hygeine Unit Policlinico Hospital Bari Italy
2 Molecular Diagnostics and Pharmacogenetics Unit IRCCS Istituto Tumori Giovanni Paolo II Bari Italy
6 Unit of Internal Medicine Guido Baccelli Department of Biomedical Sciences and Human Oncology University of Bari Medical School Bari Italy
9 Experimental Oncology and BioBank Management Unit Institutional BioBank IRCCS Istituto Tumori Giovanni Paolo II Bari Italy
8 Clinical Pathology Laboratory IRCCS Istituto Tumori Giovanni Paolo II Bari Italy
1 Science Direction IRCCS Istituto Tumori Giovanni Paolo II Bari Italy
AuthorAffiliation_xml – name: 5 Regional Epidemiological Observatory Apulia Region Bari Italy
– name: 10 Hygeine Unit Policlinico Hospital Bari Italy
– name: 7 Medical Oncology Unit IRCCS Istituto Tumori Giovanni Paolo II Bari Italy
– name: 2 Molecular Diagnostics and Pharmacogenetics Unit IRCCS Istituto Tumori Giovanni Paolo II Bari Italy
– name: 9 Experimental Oncology and BioBank Management Unit Institutional BioBank IRCCS Istituto Tumori Giovanni Paolo II Bari Italy
– name: 1 Science Direction IRCCS Istituto Tumori Giovanni Paolo II Bari Italy
– name: 3 Department of Biomedical Sciences and Human Oncology-Hygiene Section University of Bari Bari Italy
– name: 4 Emergency Department Policlinico Hospital Bari Italy
– name: 6 Unit of Internal Medicine Guido Baccelli Department of Biomedical Sciences and Human Oncology University of Bari Medical School Bari Italy
– name: 8 Clinical Pathology Laboratory IRCCS Istituto Tumori Giovanni Paolo II Bari Italy
Author_xml – sequence: 1
  givenname: Angelo Virgilio
  orcidid: 0000-0001-6495-2295
  surname: Paradiso
  fullname: Paradiso, Angelo Virgilio
– sequence: 2
  givenname: Simona
  orcidid: 0000-0001-9607-3754
  surname: De Summa
  fullname: De Summa, Simona
– sequence: 3
  givenname: Daniela
  orcidid: 0000-0003-2057-9745
  surname: Loconsole
  fullname: Loconsole, Daniela
– sequence: 4
  givenname: Vito
  orcidid: 0000-0002-5948-157X
  surname: Procacci
  fullname: Procacci, Vito
– sequence: 5
  givenname: Anna
  orcidid: 0000-0001-9383-6955
  surname: Sallustio
  fullname: Sallustio, Anna
– sequence: 6
  givenname: Francesca
  orcidid: 0000-0003-3018-5408
  surname: Centrone
  fullname: Centrone, Francesca
– sequence: 7
  givenname: Nicola
  orcidid: 0000-0001-7814-7318
  surname: Silvestris
  fullname: Silvestris, Nicola
– sequence: 8
  givenname: Vito
  orcidid: 0000-0002-4645-5188
  surname: Cafagna
  fullname: Cafagna, Vito
– sequence: 9
  givenname: Giuseppe
  orcidid: 0000-0002-6108-096X
  surname: De Palma
  fullname: De Palma, Giuseppe
– sequence: 10
  givenname: Antonio
  orcidid: 0000-0002-8129-7904
  surname: Tufaro
  fullname: Tufaro, Antonio
– sequence: 11
  givenname: Vito Michele
  orcidid: 0000-0001-8113-5959
  surname: Garrisi
  fullname: Garrisi, Vito Michele
– sequence: 12
  givenname: Maria
  orcidid: 0000-0002-1043-1256
  surname: Chironna
  fullname: Chironna, Maria
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33031048$$D View this record in MEDLINE/PubMed
BookMark eNpdkl1r2zAUhsXoWD_WvzB0MxgMb_qyLe1iELxuKxQ2km63QpaPEhXbyiSlkB-w_12naUvaK4nzPnqO4JxTdDSGERA6p-QTo6r6TBUt2St0QgWXhZQ1PTq4H6PTlG4IYUQo-gYdc044JUKeoP9zs_YdXkAMfVh6a3o8S8lsEzbjVJ7NF0UT_hYMz8H0xbUfAP8O_XaAaBLgZmX8uIts9mF8fOlCxHkF-Btk2AfBHai-4CYMaxNN9reAF3nTbd-i1870Cc4fzjP05_vFdfOzuPr147KZXRVWMJULaSRRoMqWVZyzkqoOaiFqU1XQAa9dK5xkSpYWRFW1tgLGlJXOlq1kneokP0OXe28XzI1eRz-YuNXBeH1fCHGpTcze9qBVSQShNaFcUeFsJwU4AOW44ErUrZ1cX_eu9aYdoLMw5mj6Z9LnyehXehludV0JWol6Enx4EMTwbwMp68EnC31vRgibpJkQSpUlqciEvjvs9dTkcY4T8H4P2BhSiuCeEEr0bj_0_X5M3McXnPXZ7GY0fdH3L-g77Bu5Dg
CitedBy_id crossref_primary_10_4236_aid_2022_122021
crossref_primary_10_1371_journal_pone_0273969
crossref_primary_10_1186_s13568_023_01620_0
crossref_primary_10_1007_s10570_022_04808_y
crossref_primary_10_1016_j_trac_2023_117291
crossref_primary_10_3390_app12105137
crossref_primary_10_3390_ijerph18178995
crossref_primary_10_1136_postgradmedj_2021_140176
crossref_primary_10_3390_diagnostics12112854
crossref_primary_10_3390_bios12060410
crossref_primary_10_3390_diagnostics11060975
crossref_primary_10_4103_ajop_ajop_17_24
crossref_primary_10_3390_bios13060623
crossref_primary_10_1111_jvh_13623
crossref_primary_10_30699_ijmm_15_5_584
crossref_primary_10_34172_hpp_2023_25
crossref_primary_10_1128_JCM_02026_20
crossref_primary_10_3389_fpubh_2023_1077075
Cites_doi 10.1001/jama.2020.4344
10.1136/openhrt-2018-000788
10.1056/NEJMoa2001017
10.1101/2020.04.25.20074856
10.1186/s40779-020-0233-6
10.1101/2020.03.04.20030916
10.1201/9780429258589
10.1093/clinchem/hvaa071
10.1056/NEJMc2001468
10.1016/S0140-6736(20)30183-5
10.1183/13993003.00763-2020
10.2307/2529310
10.1093/cid/ciaa310
10.1136/jcp.2008.061036
10.1002/jmv.25727
ContentType Journal Article
Copyright Angelo Virgilio Paradiso, Simona De Summa, Daniela Loconsole, Vito Procacci, Anna Sallustio, Francesca Centrone, Nicola Silvestris, Vito Cafagna, Giuseppe De Palma, Antonio Tufaro, Vito Michele Garrisi, Maria Chironna. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 30.10.2020.
Angelo Virgilio Paradiso, Simona De Summa, Daniela Loconsole, Vito Procacci, Anna Sallustio, Francesca Centrone, Nicola Silvestris, Vito Cafagna, Giuseppe De Palma, Antonio Tufaro, Vito Michele Garrisi, Maria Chironna. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 30.10.2020. 2020
Copyright_xml – notice: Angelo Virgilio Paradiso, Simona De Summa, Daniela Loconsole, Vito Procacci, Anna Sallustio, Francesca Centrone, Nicola Silvestris, Vito Cafagna, Giuseppe De Palma, Antonio Tufaro, Vito Michele Garrisi, Maria Chironna. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 30.10.2020.
– notice: Angelo Virgilio Paradiso, Simona De Summa, Daniela Loconsole, Vito Procacci, Anna Sallustio, Francesca Centrone, Nicola Silvestris, Vito Cafagna, Giuseppe De Palma, Antonio Tufaro, Vito Michele Garrisi, Maria Chironna. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 30.10.2020. 2020
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.2196/19152
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Library & Information Science
EISSN 1438-8871
ExternalDocumentID oai_doaj_org_article_9504017013914fcd84efee9f343947bc
PMC7641647
33031048
10_2196_19152
Genre Journal Article
GroupedDBID ---
.4I
.DC
29L
2WC
36B
53G
5GY
5VS
77K
7RV
7X7
8FI
8FJ
AAFWJ
AAKPC
AAWTL
AAYXX
ABDBF
ABIVO
ABUWG
ACGFO
ADBBV
AEGXH
AENEX
AFKRA
AFPKN
AIAGR
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALSLI
AOIJS
BAWUL
BCNDV
BENPR
CCPQU
CITATION
CNYFK
CS3
DIK
DU5
DWQXO
E3Z
EAP
EBD
EBS
EJD
ELW
EMB
EMOBN
ESX
F5P
FRP
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
KQ8
M1O
M48
NAPCQ
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
RNS
RPM
SJN
SV3
TR2
UKHRP
XSB
CGR
CUY
CVF
ECM
EIF
NPM
77I
7X8
PPXIY
PRQQA
PUEGO
5PM
ID FETCH-LOGICAL-c429t-8a809e95b26332519de7447a66ede37fb4f82985ce466bc6e229c8fc5b82d9d83
IEDL.DBID M48
ISSN 1438-8871
1439-4456
IngestDate Wed Aug 27 01:29:59 EDT 2025
Thu Aug 21 14:09:53 EDT 2025
Fri Sep 05 13:18:19 EDT 2025
Thu Jan 02 22:58:27 EST 2025
Tue Jul 01 02:05:51 EDT 2025
Thu Apr 24 22:55:51 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords COVID-19
serological test
SARS-CoV-2
RT-PCR
Language English
License Angelo Virgilio Paradiso, Simona De Summa, Daniela Loconsole, Vito Procacci, Anna Sallustio, Francesca Centrone, Nicola Silvestris, Vito Cafagna, Giuseppe De Palma, Antonio Tufaro, Vito Michele Garrisi, Maria Chironna. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 30.10.2020.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on http://www.jmir.org/, as well as this copyright and license information must be included.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c429t-8a809e95b26332519de7447a66ede37fb4f82985ce466bc6e229c8fc5b82d9d83
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-5948-157X
0000-0003-2057-9745
0000-0001-7814-7318
0000-0002-4645-5188
0000-0002-8129-7904
0000-0001-6495-2295
0000-0001-9607-3754
0000-0002-1043-1256
0000-0002-6108-096X
0000-0001-8113-5959
0000-0001-9383-6955
0000-0003-3018-5408
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.2196/19152
PMID 33031048
PQID 2449955060
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_9504017013914fcd84efee9f343947bc
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7641647
proquest_miscellaneous_2449955060
pubmed_primary_33031048
crossref_primary_10_2196_19152
crossref_citationtrail_10_2196_19152
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-10-30
PublicationDateYYYYMMDD 2020-10-30
PublicationDate_xml – month: 10
  year: 2020
  text: 2020-10-30
  day: 30
PublicationDecade 2020
PublicationPlace Canada
PublicationPlace_xml – name: Canada
– name: Toronto, Canada
PublicationTitle Journal of medical Internet research
PublicationTitleAlternate J Med Internet Res
PublicationYear 2020
Publisher JMIR Publications
Publisher_xml – name: JMIR Publications
References ref13
ref15
ref14
ref20
ref11
ref21
ref2
ref1
ref17
ref16
ref19
ref18
ref8
ref7
Altman, DG (ref12) 1990
ref9
Landis, JR (ref10) 1977; 33
ref4
ref3
ref6
ref5
References_xml – ident: ref4
– ident: ref3
  doi: 10.1001/jama.2020.4344
– ident: ref21
  doi: 10.1136/openhrt-2018-000788
– ident: ref2
  doi: 10.1056/NEJMoa2001017
– ident: ref7
– ident: ref18
  doi: 10.1101/2020.04.25.20074856
– ident: ref5
  doi: 10.1186/s40779-020-0233-6
– ident: ref16
  doi: 10.1101/2020.03.04.20030916
– year: 1990
  ident: ref12
  publication-title: Practical Statistics for Medical Research
  doi: 10.1201/9780429258589
– ident: ref11
  doi: 10.1093/clinchem/hvaa071
– ident: ref6
  doi: 10.1056/NEJMc2001468
– ident: ref1
  doi: 10.1016/S0140-6736(20)30183-5
– ident: ref17
  doi: 10.1183/13993003.00763-2020
– volume: 33
  start-page: 159
  issue: 1
  year: 1977
  ident: ref10
  publication-title: Biometrics
  doi: 10.2307/2529310
– ident: ref9
– ident: ref8
– ident: ref20
  doi: 10.1093/cid/ciaa310
– ident: ref15
– ident: ref19
  doi: 10.1136/jcp.2008.061036
– ident: ref13
  doi: 10.1002/jmv.25727
– ident: ref14
SSID ssj0020491
Score 2.4069934
Snippet Real-time polymerase chain reaction (RT-PCR) testing for the identification of viral nucleic acid is the current standard for the diagnosis of SARS-CoV-2...
BackgroundReal-time polymerase chain reaction (RT-PCR) testing for the identification of viral nucleic acid is the current standard for the diagnosis of...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage e19152
SubjectTerms Betacoronavirus - genetics
Betacoronavirus - immunology
Betacoronavirus - isolation & purification
Clinical Laboratory Techniques - methods
Coronavirus Infections - diagnosis
Coronavirus Infections - immunology
Coronavirus Infections - virology
COVID-19
COVID-19 Testing
COVID-19 Vaccines
Female
Humans
Immunoglobulin G - analysis
Immunoglobulin G - immunology
Immunoglobulin M - analysis
Immunoglobulin M - immunology
Male
Middle Aged
Original Paper
Pandemics
Pneumonia, Viral - diagnosis
Pneumonia, Viral - immunology
Pneumonia, Viral - virology
Real-Time Polymerase Chain Reaction - methods
SARS-CoV-2
Sensitivity and Specificity
Serologic Tests - methods
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB5KDqFQSpu-3DRBhdCbideSZSm3dNsQCill25TcjJ5kIdghuznsD-j_7owtb3dDoZdeNbIlNDOaGWnmE8BRpZ2IFjXNOIEBivIR90HpcjSuUToupBNU73zxVZ5fii9X1dXGU1-UEzbAAw8Ld6wrFDMCDed6IqLzSoQYgo6cSjpr62j3LXQxBlMp1EK_d7ILTyjRGUXsGIOSqtyyPD1A_9-8yofJkRvW5uwZPE1uIjsdpvccHoV2Dw5SkQH7wFIVEa0qS-q5B7sX6aL8Bfyamdu5Z7gTjJsbQ0aY1YKZFptPZ9_zafczL9kMHcWc6kDYt-5mRSdUi8Cm12beEqkvehi_xBEZuovsU1iGgdDFjV-dsOkfJHFG-Ymrl3B59vnH9DxPLy7kDu3SMldGFTroypaSc6pp9aEWojZSBh94Ha2IqtSqckFIaZ0MZamdiq6yqvTaK_4KdtquDW-ASRUMj2j_VSCIPW28mhQmGumlLazhGRyN3GhcgiOnVzFuGgxLiGlNz7QMDtfdbgf8jYcdPhIr10SCy-4bUIiaJETNv4Qog_ejIDSoXnRnYtrQ3S8a9H60rgiFMYPXg2Csh-KccFWFyqDeEpmtuWxT2vl1D-FdS0FAbm__x-T34XFJhwBkUIt3sLO8uw8H6Ckt7WGvFL8BllARdA
  priority: 102
  providerName: Directory of Open Access Journals
Title Rapid Serological Assays and SARS-CoV-2 Real-Time Polymerase Chain Reaction Assays for the Detection of SARS-CoV-2: Comparative Study
URI https://www.ncbi.nlm.nih.gov/pubmed/33031048
https://www.proquest.com/docview/2449955060
https://pubmed.ncbi.nlm.nih.gov/PMC7641647
https://doaj.org/article/9504017013914fcd84efee9f343947bc
Volume 22
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFD5sLYTCGF1389YaDcrevCW2LEuDUtqspQzSlWwZfTOSLK2BYHdJCssP2P_eOY6dJaVPe_GDJdnG5_YdSecTwGGqLPcGLU1bjgmKLDz6QWEjDK5e2IQLy6neeXApLkb8y3W6tpuw-YGzB1M7Ok9qNJ18-P1rcYwGf0TbmFGBPmLKkaIX3sZgJCj_GvDVQkKMALjOuTgteCJY6MCTjWE70MGMHjEOHQC0FplqAv-HUOf9zZNr0eh8F542MJKdLOX-DB65cg8OmiIE9p41VUb011ljvnvQGTQL6c_hz1DfjguGnqJ1fgwFpRczpku8fTL8FvWrH1HMhggkI6oTYVfVZEEzWDPH-jd6XFJTXRTRjsQ3MoST7LObu2VD5dce9Yn1_zGNM9q_uHgBo_Oz7_2LqDmRIbIYt-aR1LKrnEpNLJKEal4Ll3GeaSFc4ZLMG-5lrGRqHRfCWOHiWFnpbWpkXKhCJi9hq6xK9xqYkE4nHvGBdETBp3Qhe13ttSiE6RqdBHDYSiO3DV05nZoxyTFtIfnltfwCCFfdbpf8HPc7nJIoV41Ep13fqKY_88Y6c5WiLyNm-kT1uLeF5M47p3xCdcOZsQG8axUhR_OjNRVduupuliM6UiollsYAXi0VY_WqVrECyDZUZuNbNlvK8U1N8Z0JTkRvb_575FvYiWlmgKJsdx-25tM7d4DwaW5CeJxdZyFsn55dXg3DehICr4Pe17A2nb8zAR13
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rapid+Serological+Assays+and+SARS-CoV-2+Real-Time+Polymerase+Chain+Reaction+Assays+for+the+Detection+of+SARS-CoV-2%3A+Comparative+Study&rft.jtitle=Journal+of+medical+Internet+research&rft.au=Paradiso%2C+Angelo+Virgilio&rft.au=De+Summa%2C+Simona&rft.au=Loconsole%2C+Daniela&rft.au=Procacci%2C+Vito&rft.date=2020-10-30&rft.pub=JMIR+Publications&rft.issn=1439-4456&rft.eissn=1438-8871&rft.volume=22&rft.issue=10&rft_id=info:doi/10.2196%2F19152&rft_id=info%3Apmid%2F33031048&rft.externalDocID=PMC7641647
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1438-8871&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1438-8871&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1438-8871&client=summon